We will be at two investor conferences in November. @Guggenheim 3rd Annual Healthcare Innovation Conference — Nov. 9, Boston. Fireside chat at 9:30 a.m. ET, webcast available. @Jefferies Global Healthcare Conference — Nov. 16-19, London. Our leadership team will be available for one-on-one meetings at both. ir.satellos.com/news/news-de… #Duchenne #FSHD #MuscleRegeneration $MSLE $MSCL.TO

Duchenne is caused by mutations in the dystrophin gene. FSHD is caused by abnormal activation of DUX4. Genetically, they have nothing in common, but both converge on the same consequence: muscle stem cells can no longer repair muscle as they should. That is what we target — the repair biology itself, rather than the genetic cause. satellos.com #Duchenne #FSHD #muscleregeneration $MSLE $MSCL.TO

Muscle is built to repair itself. Muscle stem cells replace what ordinary use wears down. In degenerative muscle diseases, that repair process is disrupted and damage outpaces repair. In both Duchenne and FSHD, the genetic mutations causing the conditions disrupt the body’s natural muscle regenerative process. Different genetics, the same underlying problem. Closing that gapbetween muscle damage and repair, is the focus of our work. Visit satellos.com to learn more. #Duchenne #FSHD #MuscleRegeneration $MSLE $MSCL.TO

We have activated our first U.S. site for TRAILHEAD @UCLAHealth. TRAILHEAD is an open-label Phase 2 study of forazapadin in adults with #Duchenne muscular dystrophy. Learn more about TRAILHEAD at satellos.com/patients. #muscleregeneration $MSLE $MSCL.TO

That's a wrap on the 31st Annual Congress of the @WorldMuscleSoc in Hiroshima. Four posters, five days, and a lot of good conversations about #muscleregeneration. Thank you to everyone who stopped by Booth 6 or found us at the poster sessions. WMS Posters are available here: satellos.com/science/#public… #WMS2026 #Duchenne #FSHD $MSLE $MSCL.TO

The United States Patent and Trademark Office (@uspto) has issued a composition of matter patent covering forazapadin and a broader class of AAK1 inhibitors within our #muscleregeneration platform, with protection through September 2044. ir.satellos.com/news/news-de… #Duchenne #FSHD $MSLE $MSCL.TO

Enrollment is complete in BASECAMP, our Phase 2 trial of forazapadin in ambulatory boys with Duchenne muscular dystrophy. Thank you to the families who chose to take part, and to the investigators and site teams who made it possible. Full details here: tinyurl.com/2ejmb3ww #Duchenne #MuscleRegeneration $MSLE $MSCL.TO

We’re expanding forazapadin (SAT-3247) into a second degenerative muscle disease. The @FDA has cleared our IND in facioscapulohumeral muscular dystrophy (FSHD), and we’re grateful to the FSHD Canada Foundation for its support as we move toward a Phase 2 study later this year. Full details here: tinyurl.com/36t4ft4d #FSHD #MuscleRegeneration #MuscularDystrophy $MSLE $MSCL.TO

September is Newborn Screening Awareness Month. Earlier diagnosis can help children with #Duchenne muscular dystrophy and their families access care and support sooner. Join us in recognizing the advocacy groups working to advance newborn screening and help bring earlier diagnosis to more families. #NewbornScreeningAwarenessMonth

Next stop: Hiroshima. At the 31st Annual Congress of the World Muscle Society (WMS), the Satellos team will present four scientific posters highlighting progress across our research programs. If you're attending WMS, we'd be glad to connect, just stop by Booth 7 or any of our posters. Read the full announcement: ir.satellos.com/news/news-de… $MSLE $MSCL.TO

Satellos announced today that its orally administered small-molecule drug candidate, previously known as SAT-3247, has been assigned the International Nonproprietary Name “forazapadin.” More details here: ir.satellos.com/news/news-de… $MSLE $MSCL.TO

The Satellos team wore red in recognition of #WorldDuchenneAwarenessDay, showing our support for the Duchenne community. This year's theme, #AccessChangesLives, reminds us that together we can help raise awareness and advocate for greater access for everyone living with #Duchenne muscular dystrophy. #WDAD2026 $MSLE $MSCL.TO

We'll be in New York this September to meet with investors and share updates on our progress. Learn more in today's press release: ir.satellos.com/news/news-de… #MuscleRegeneration $MSLE $MSCL.TO

#SatellosStories: Meet Bill Aschenbach. Bill's career took the long way around. He started as a muscle biologist, then followed a chance tip out of the lab and into medical affairs. Over 25 years he learned every corner of the field across companies large and small, building teams from the ground up more than once. It all led back to where he started: muscle. Today he leads Medical Affairs at Satellos. His story, in his own words. ↓ $MSLE $MSCL

Satellos ($MSLE, $MSCL.TO) announced today its second quarter financial results and recent company progress. Full details here: ir.satellos.com/news/news-de…

Muscle comes with its own repair crew. Stem cells sit alongside muscle fibers, ready to respond when damage occurs. They divide to replenish themselves and create the muscle-building cells needed for repair. In Duchenne muscular dystrophy, that repair process breaks down. Too few muscle-building cells are produced, and repair can’t keep up with ongoing damage. See how it happens. #MuscleRegeneration #Duchenne $MSLE $MSCL

#SatellosStories: Meet Cassie McGurk. Cassie's path to biotech wasn't a straight line — FDA attorney, time away to raise her family, then a return to the kind of complex, layered work she's drawn to. Today, as senior director of Program Management at Satellos, she keeps the many moving pieces of a clinical-stage biotech in sync. Watch this clip to meet her in her own words → $MSLE $MSCL.TO